The FINANCIAL -- PRINCETON, N.J.-- Bristol-Myers Squibb Company on July 5 announced that the European Commission (EC) has expanded the indication for Sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), and to include a powder for oral suspension ...

The FINANCIAL -- Hospitals are a central part of every healthcare system, and need to regularly evolve their infrastructure and facilities to keep up with new treatments and ...

The FINANCIAL -- Tobacco use has declined markedly since 2000, according to a new WHO report, but the reduction is insufficient to meet globally agreed targets aimed at protecting people from death ...

The FINANCIAL -- The World Health Organization certified on June 12 that Paraguay as having eliminated malaria, the first country in the Americas to be granted this status since Cuba in ...

The FINANCIAL -- The number of cancer cases is growing, and while the effectiveness of treatments is increasing, it is important not to overlook the side effects of these therapies, some of which ...

The FINANCIAL -- The first major paper looking at the causes and consequences of meningitis in the UK has found that viruses are now the most common cause of meningitis in adults and a cause of ...